Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist
Authors:
- 29 September 2020
- journal article
- review article
- Published by Springer Nature in Current Dermatology Reports
- Vol. 9 (4) , 231-243
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- DRESS syndromeJournal of the American Academy of Dermatology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot studyThe Lancet Oncology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapyCancer Immunology, Immunotherapy, 2004
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences, 2002
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- SCORTEN: A Severity-of-Illness Score for Toxic Epidermal NecrolysisJournal of Investigative Dermatology, 2000